Skip to main content
SpringerLink
Log in

Treatment of Colorectal Cancer

Current Guidelines and Future Prospects for Drug Therapy

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 July 1997

Summary

Colorectal carcinoma is one of the most common cancers in Western countries (yearly incidence rate of 1: 3000), and represents, after lung cancer, the second leading cause of deaths due to cancer. During the past decades, knowledge about this carcinoma has considerably increased, but little progress has been made in improvement in patient survival. At least 40% of patients with colorectal cancer will have metastases sometime during the course of their illness.

In colon cancer, the first therapeutic approach is surgery, but the important role of adjuvant chemotherapy in these patients, in terms of disease-free survival and overall survival benefit, is now well established. Until today, standard therapy was represented by fluorouracil plus levamisole and/or calcium folinate (folinic acid). Other strategies are represented by monoclonal antibodies (mAb), which improve survival, (with a decrease in mortality by 32%), and by portal vein fluorouracil, alone or in combination with systemic therapy. In rectal cancer, the best results have been obtained with a combination of radiotherapy and chemotherapy.

In advanced colorectal cancer, a standard treatment has not yet been established. This disease is usually considered as poorly chemosensitive and for more than 30 years fluorouracil has been the standard drug. Tumour response rates (partial + complete) for patients treated with bolus intravenous fluorouracil are 10 to 15%, with a median survival about 1 year.

Many attempts have been made to improve these results. Biochemical modulation of fluorouracil is one of the most interesting strategies developed in the last few years in an attempt to increase the therapeutic index of this compound. Another way has been to administer fluorouracil by continuous infusion. Further innovative compounds such as irinotecan and raltitrexed are now being evaluated in clinical trials. Preliminary data from phase II and III studies have provided encouraging results on the use of these new drugs. In metastatic disease confined to the liver, the possibility of locoregional therapy through implantable pumps should be taken into consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T. Cancer statistics. Cancer J Clin 1993; 43: 7–10

    Article  CAS  Google Scholar 

  2. Astler VA, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139: 846–52

    Article  PubMed  CAS  Google Scholar 

  3. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 1984; 310: 737–41

    Article  Google Scholar 

  4. Scivetti P, Riccardi A, Marsano B, et al. Flow cytometric DNA index in the prognosis of colorectal cancer. Cancer 1991; 67: 1921–7

    Article  PubMed  Google Scholar 

  5. Moertel CG, O’Fallon JR, Go VL, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603–6

    Article  PubMed  CAS  Google Scholar 

  6. Wolmark N, Fisher B, Wieand HS. The prognostic value of the modifications of the Dukes’ C class of colorectal cancer. Ann Surg 1986; 203: 115–22

    Article  PubMed  CAS  Google Scholar 

  7. Buyse M, Zeleniuch-Jacquotte A, Chalmers T. Adjuvant therapy of colorectal cancer: why we still don’t know. JAMA 1988; 259: 3571–8

    Article  PubMed  CAS  Google Scholar 

  8. Gray R, James R, Mossman J, Stenning S. AXIS — a suitable case for treatment. Br J Cancer 1991; 63: 851–5

    Article  Google Scholar 

  9. Arnaud JP, Buyse M, Nordlinger B, et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg 1989; 76: 284–9

    Article  PubMed  CAS  Google Scholar 

  10. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447–56

    PubMed  CAS  Google Scholar 

  11. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8

    Article  PubMed  CAS  Google Scholar 

  12. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990: 264: 1440–50

    Google Scholar 

  13. Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in adjuvant therapy of colorectal cancer. Ann Oncol 1996; 7: 41–6

    Article  Google Scholar 

  14. Labianca R, Marsoni S, Pancera G, et al. International Multicentre Pooled Analyses of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44

    Article  Google Scholar 

  15. Wolmark N, Rockette H, Mamounas EP, et al. The relative efficacy of 5-FU + Leucovorin (FU-LV), 5-FU + Levamisole (FU-LEV), and 5-FU + Leucovorin + Levamisole (FU-LV-LEV) in patients with Dukes’ B and C carcinoma of the colon: first report of NSABP-C-04 [abstract]. Proceedings of American Society of Clinical Oncology; 1996 May 18–21: Philadelphia; 15: 460

  16. Haller DG, Catalano PJ, Macdonald JS, et al. Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089 [abstract]. Proceedings of American Society of Clinical Oncology; 1996 May 18–21: Philadelphia; 15: 486

  17. Matsuda T, Yasutomi M, Kikuchi K, et al. Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan. Jap J Cancer Chemother 1991; 18(3): 416–9

    Google Scholar 

  18. Takashima S, Tomita F, Saito H, et al. Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer-comparisons between tegafur (FT) and UFT. Jpn J Cancer Chemother 1991; 18: 2315–24

    CAS  Google Scholar 

  19. Riethmueller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastases of epithelial cancers. Curr Opin Immunol 1992; 4: 647–55

    Article  Google Scholar 

  20. Riethmueller G, Schneider-Gaedicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5: 732–9

    Article  CAS  Google Scholar 

  21. Riethmueller G, Schneider-Gaedicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994; 343: 1177–83

    Article  Google Scholar 

  22. Riethmueller G, Holz E, Schlimok G, et al. Monoclonal antibody (MAB) adjuvant therapy of Dukes C colorectal carcinoma: 7-year update of a prospective randomized trial [abstract]. Proceedings of American Society of Clinical Oncology; 1996 May 18–21: Philadelphia; 15: 1385

    Google Scholar 

  23. Hoover HC, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11: 390–9

    PubMed  Google Scholar 

  24. Vermorken JB, Claessen AME, Gall HE, et al. Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes’ B2, B3 or C colon cancer [abstract]. Proceedings of American Society of Clinical Oncology; 1996 May 18–21: Philadelphia; 15: 444

    Google Scholar 

  25. Copeland EM, Miller LD, Jones RS, et al. Prognostic factors in carcinoma of the colon and rectum. Am J Surg 1968; 116: 875–81

    Article  PubMed  CAS  Google Scholar 

  26. Pestana C, Reitemeier RJ, Moertel CG, et al. The natural history of carcinoma of the colon and rectum. Am J Surg 1964; 108: 826–9

    Article  PubMed  CAS  Google Scholar 

  27. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of national surgical adjuvant breast and bowel project protocol C-02. J Clin Oncol 1990; 8: 1466–75

    PubMed  CAS  Google Scholar 

  28. Piedbois P, Buyse M, Gray R, et al. Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer [abstract]. Proceedings of American Society of Clinical Oncology; 1995 May 20–23: Los Angeles; 14: 444

    Google Scholar 

  29. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 and C adenocarcinoma. Cancer 1991; 68: 879–8

    Article  PubMed  CAS  Google Scholar 

  30. Moertel CG, Fleming TR, MacDonald JS, et al. Intergroup study of fluorouracil plus Levamisole as adjuvant therapy for study II/Dukes B2 colon cancer. J Clin Oncol 1995; 13: 2936–43

    PubMed  CAS  Google Scholar 

  31. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B vs Dukes’ C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04) [abstract]. Proceedings of American Society of Clinical Oncology; 1996 May 17–21: Philadelphia; 15: 461

    Google Scholar 

  32. O’Connell MJ, Laurie JA, Shepherd L, et al. A prospective evaluatin of chemotherapy duration and regimen as surgical adjuvant treatment for high risk colon cancer: a collaborative trial of the National Cancer Institute of Canada clinical trials. [abstract] Proceedings of American Society of Clinical Oncology; 1996 May 18–21: Philadelphia; 15: 478

  33. Minsky BD. Preoperative combined modality treatment for rectal cancer. Oncology 1994; 8: 53–68

    PubMed  CAS  Google Scholar 

  34. Dahl O, Horn A, Morild I, et al. Low-dose pre-operative radiation postpones recurrences in operable rectal cancer. Cancer 1990; 66: 2286–92

    Article  PubMed  CAS  Google Scholar 

  35. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1990; 66: 49–55

    Article  Google Scholar 

  36. Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of randomized study of the EORTC. Ann Surg 1988; 606–14

    Google Scholar 

  37. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 312: 1465

    Google Scholar 

  38. Treurniet-Donker AD, van Putten WLJ, Weroldsma JGJ, et al. Postoperative radiation therapy for rectal cancer. Cancer 1991; 67: 2042–8

    Article  PubMed  CAS  Google Scholar 

  39. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21–9

    Article  PubMed  CAS  Google Scholar 

  40. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and evaluation of late secondary effects. Dis Colon Rectum 1993; 66: 49–55

    Google Scholar 

  41. Second report on an MRC Working Party. The evaluation of low-dose pre-operative X-ray therapy in the management of operable rectal cancer: results of a randomly controlled trial. Br J Surg 1984; 71: 21–30

    Article  Google Scholar 

  42. Gunderson LL, Grohen AM, Dosoretz DE, et al. Residual unresectable or recurring colorectal cancer: external beam irradiation and intraoperative electron beam boost +/− resection. Int J Radiat Oncol Biol Phys 1983; 9: 1597–1605

    Article  PubMed  CAS  Google Scholar 

  43. Suzuki K, Gunderson LL, Devine RM, et al. Intraoperative irradiation following palliative surgery for locally recurrent rectal cancer. Cancer 1995; 75: 939–52

    Article  PubMed  CAS  Google Scholar 

  44. Thomas PRM, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988; 13: 245–52

    Article  PubMed  CAS  Google Scholar 

  45. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709–15

    Article  PubMed  CAS  Google Scholar 

  46. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502–7

    Article  PubMed  Google Scholar 

  47. Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976; 37: 2861–5

    Article  PubMed  CAS  Google Scholar 

  48. Seifert P, Baker LH, Reed MD, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–8

    Article  PubMed  CAS  Google Scholar 

  49. Rougier P, Paillot B, Lapplanche A, et al. End result of multi-center randomized trial comparing 5FU in continuous systemic infusion to bolus administration in measurable metastatic colorectal cancer [abstract]. Proceedings of the American Society of Clinical Oncology; 1992 May 17–19: San Diego; 11: 465

  50. Weinerman B, Shah A, Fields A, et al. Systemic infusion versus bolus chemotherapy in measurable colorectal cancer. Am J Clin Oncol 1992; 15: 518–23

    Article  PubMed  CAS  Google Scholar 

  51. Lokich JJ, Ahlgren JD, Gullo JJ, et al. Aprospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–32

    PubMed  CAS  Google Scholar 

  52. Hansen R, Ryan L, Anderson T, et al. A phase III trial of bolus 5FU versus protracted infusion 5FU +/− cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST 2286) [abstract]. Proceeding of American Society of Clinical Oncology, 1992 May 17–19, San Diego; 11: 499

  53. Leichman CG, Fleming TR, Muggia M, et al. Fluorouracil (5FU) schedules and modulation in advanced colorectal cancer (CRC). A Southwest Oncology Group (SWOG) screening trial [abstract]. Proceedings of the American Society of Clinical Oncology 1993 May 16–18: Orlando, Florida; 12: 583

  54. Machover D, Goldschmid E, Chollet P. Treatment of advanced colorectal and gastric adenocarcinomas with 5 -fluorouracil and high-dose folinic acid. J. Clin Oncol 1986; 4: 685–96

    PubMed  CAS  Google Scholar 

  55. Buroker TR, O’Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14–20

    PubMed  CAS  Google Scholar 

  56. Valsecchi R, Labianca R, Cascinu S, et al. High dose (HD) versus low dose (LD) L-Leucovorin (LLV)as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): a ‘GISCAD’ phase III study [abstract]. Proceedings of American Society of Clinical Oncology, 1995 May 20–23: Los Angeles; 14: 457

  57. Jaeger J, Heike M, Bernhard H, et al. Weekly high-dose Leucovorin versus low-dose Leucovorin combined with Fluorouracil an advanced colorectal cancer: results of a randomized multicentric trial. J Clin Oncol 1996; 14:8, 2274–9

    CAS  Google Scholar 

  58. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960–9

    Google Scholar 

  59. Nobile MT, Vidili MG, Sobrero A, et al. 5-fluorouracil alone or combined with high-dose folinic acid in advanced colorectal cancer patients [abstract]. Proceedings of American Society of Clinical Oncology, 1988 may 22–24: New Orleans; 7: 371

  60. Petrelli N, Douglass HO, Herrera, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal cancer: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–26

    PubMed  CAS  Google Scholar 

  61. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–65

    PubMed  CAS  Google Scholar 

  62. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal cancer with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential, methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427–36

    PubMed  CAS  Google Scholar 

  63. Di Costanzo F, Bartolucci R, Sofra M, et al. 5-fluorouracil alone vs high dose folinic acid and 5-FU in advanced colorectal cancer. A randomized tril of the Italian Oncology Group for Clinical Research (GOIRC) [abstract]. Proceedings of American of Society of Clinical Oncology; 1989 May 21–23: San Francisco, California; 8: 410

  64. Labianca R, Pancera G, Aitini E, et al. Folinic acid + 5-fluorouracil (5FU) versus equidose 5FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991; 2: 673–9

    PubMed  CAS  Google Scholar 

  65. Poon MA, O’Connel MJ, Moertel CG, et al. Biochemical modulation of fluorouracil. Evidence of significant improvement of survival and quality of life in patient with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–18

    PubMed  CAS  Google Scholar 

  66. Doroshow JH, Multauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patient previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491–501

    PubMed  CAS  Google Scholar 

  67. Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–75

    PubMed  CAS  Google Scholar 

  68. Nordic Gastrointestinal Tumor Adjuvant therapy Group. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 1989; 7: 1437–46

    Google Scholar 

  69. Herrmann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil (FU) vs FU alone in metastatic colorectal cancer. Ann Oncol 1992; 3: 539–43

    PubMed  CAS  Google Scholar 

  70. Machiavelli M, Leone BA, Romero A, et al. Advanced colorectal carcinoma: A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 1991; 14: 211–7

    PubMed  CAS  Google Scholar 

  71. Blijham GH, Stellestags J, Sahmoud T, et al. The modulation of high-dose 5-fluorouracil with low dose methotrexate in metastatic colorectal cancer: A phase III study of the EORTC GI Cancer Cooperative Group. Proceeedings of American Society of Clinical Oncology; 1993 May 16–18; Orlando, Florida: 12: 586

  72. Delfino C, Caccia G, Maniago O. 5-Fluorouracil alone versus methotrexate + leucovorin + FU in patients with metastatic colorectal cancer. Proceedings of American Society of Clinical Oncology; 1992 May 17–19; San Diego; 11: 521

  73. Abad A, Garcia P, Gravalos C, et al. Phase III trial with methotrexate, 5-FU and high-dose leucovorin vs. 5-FU, leucovorin vs. 5-FU in advanced and metastatic colorectal cancer. Proceedings of American Society of Clinical Oncology; 1993; May 16–18; Orlando, Florida; 12: 459

  74. Cunningham D, Zalcberg J, Smith IE, et al. Tomudex: a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol 1996; 7: 179–82

    Article  PubMed  CAS  Google Scholar 

  75. Cunningham D, Zalcberg J, Rath U. et al. Tomudex: result of randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31: 1945–54

    Article  Google Scholar 

  76. Bugat R, Rougier P, Brunet P, et al. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer: results of a multicentric open phase II study [abstract]. 5th International Congress of Anticancer Chemotherapy; 1995 Jan 31–Feb 3: Paris, France: S775

  77. Pitot HC, Weder D, O’Connell MJ, et al. A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study [abstract]. Proceedings of American Society of Clinical of Oncology; 1994 May 14–17: Dallas, Texas; 13: 573

  78. Shimada Y, Yashino M, Wakui A, et al. Phase II study of CPT-11, a new camptotecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–13

    PubMed  CAS  Google Scholar 

  79. Rothenberg ML, Eckardt JR, Burric III HA, et al. Irinotecan (CPT-11) as second line therapy for pts with 5-FU refractory colorectal cancer [abstract]. Proceedings of American Society of Clinical of Oncology; 1994 May 14–17: Dallas; 13: 578

  80. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil alteration of the pharmacokinetics of CPT-11 and SN-30 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86: 1096–8

    Article  PubMed  CAS  Google Scholar 

  81. Northover J.M, Terblanche J. A new look at the arterial supply of the bile duct in men: its surgical implication. Br J Surg 1979; 66: 379–81

    Article  PubMed  CAS  Google Scholar 

  82. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327–34

    Article  PubMed  CAS  Google Scholar 

  83. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459

    PubMed  CAS  Google Scholar 

  84. Hohn D, Stagg R, Friedman M, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group Trial. J Clin Oncol 1989; 7: 1646

    PubMed  CAS  Google Scholar 

  85. Chang AE, Schneider PD, Sugarbaker. A prospective randomized trial of regional versus systemic continuous 5-Fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685

    Article  PubMed  CAS  Google Scholar 

  86. Martin JK, O’Connell MJ, Wieand HS, et al. Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 1990; 125: 1022

    Article  PubMed  Google Scholar 

  87. Wagman LD, Kemeny MM, Leong L, et al. A prospective randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8(11): 1995

    Google Scholar 

  88. Niederhuber JE. Arterial chemotherapy for metastatic colorectal cancer in the liver. Conference Advances in Regional Cancer Therapy. Gissen, West Germany, 1985

  89. Piedbois P, Buyse M, Kemeny N, et al. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88(5): 252–8

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, S. Carlo Borromeo Hospital, Milan, Italy

    Roberto Labianca, Maria Adelaide Pessi & Giuseppina Zamparelli

Authors
  1. Roberto Labianca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Adelaide Pessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppina Zamparelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03260139.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Labianca, R., Pessi, M.A. & Zamparelli, G. Treatment of Colorectal Cancer. Drugs 53, 593–607 (1997). https://doi.org/10.2165/00003495-199753040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199753040-00005

Keywords

Search

Navigation